We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Neoleukin Therapeutics, Inc's financial performance into perspective.
January 8, 2021
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
January 7, 2021
December 10, 2020
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
January 14, 2021 at 4:30 PM EST
November 23, 2020 at 7:00 AM EST